CORRECTION — Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference

IGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease

Data provide strong rationale for continued development in Huntington’s and other slowly progressive neurodegenerative diseases, including Alzheimer’s

ROCHESTER, N.Y., Oct. 29, 2020 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by Vaccinex, Inc. (Nasdaq: VCNX) please note that the original version of this press release, the third paragraph indicated that interested participants would be able to register for HSG at no charge, however there is a nominal fee and interested participants may register for the event here. The corrected release follows:

Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it will report additional data from its recently completed Phase 2 SIGNAL study of pepinemab in Huntington’s disease (HD) at the virtual Huntington Study Group 2020:HD in Focus medical conference, which will take place from October 29-31, 2020. These new data suggest that pepinemab has the potential to provide cognitive benefit and slow brain atrophy in HD patients.

Dr. Maurice Zauderer, chief executive officer of Vaccinex, will present, “Learnings from the SIGNAL Phase 2 Study of Treatment with Pepinemab Antibody,” at 10:00 am ET on Friday, October 30.

The original version of this press release indicated that interested participants would be able to register for HSG at no charge. There is a nominal fee and interested participants may register for the event here.

Further analysis of data from the SIGNAL study continues to provide insights into pepinemab’s treatment effects. Key observations from post-hoc and pre-specified analyses to be reported at the conference include:

  • Highly significant treatment benefit for pepinemab as reflected in the HD-Cognitive Assessment Battery (HD-CAB) Composite Index
  • A further signal of benefit was provided by analysis of treating physicians’ Clinical Global Impression of Change in a subpopulation of patients with more advanced disease progression
  • Pre-specified exploratory volumetric MRI analysis of brain in patients with early manifest disease demonstrate treatment related reduction in brain atrophy

The company believes these results provide a strong rationale for continued development of pepinemab as a treatment option in HD as well as in other slowly progressive neurodegenerative diseases. As for any well-designed phase 2 study, the main goal of SIGNAL was to identify a patient population that can benefit from the selected treatment and to characterize endpoints that can be employed to evaluate treatment benefit in this population. Safety data from this study also indicate that pepinemab is well-tolerated and suggest that there will be an opportunity for combination treatment with other agents based on an independent mechanism of action that are currently in development. The treatment discontinuation and study drop-out rates were remarkably low over the extended study time period and there did not appear to be an increase in serious adverse events relative to placebo.

READ MORE

SURCE: Vaccinex



0 Condivisioni